New Day Diagnostics

09/02/2026

You don't have to wait for symptoms to start thinking about colorectal health.

If you're 45 or older, colorectal cancer screening should be part of your preventive health routine.

There are multiple ways to get screened. The important thing is finding an appropriate option you'll actually complete—and following through on any recommended next steps.

Your health. Your future. Start the conversation today.

07/31/2026

Screening is not about finding something wrong.

It’s about staying ahead.

A simple conversation with your healthcare provider today can help protect your tomorrow.

Make preventive health a priority.

07/30/2026

🚀 Another milestone for New Day Diagnostics.

We're pleased to share that a collaborative research study involving New Day Diagnostics has been published in JAMA Oncology.

This investigator-initiated study, led by the University Hospital of Nancy and an outstanding international team of clinical and scientific collaborators, explores circulating biomarkers for the early detection and management of liver cancer. New Day Diagnostics contributed reagents and technical support to the research.

We congratulate Abderrahim OUSSALAH, MD, PhD and all the investigators on this important scientific contribution and are grateful to have supported this collaborative effort. Advancing cancer diagnostics depends on strong partnerships among academic institutions, clinicians, and industry, and we remain committed to supporting high-quality research that has the potential to improve early cancer detection and patient outcomes.

Congratulations to all of the authors and collaborators on this publication.


https://zurl.co/016TY

This diagnostic study evaluates whether methylated SEPT9 improves detection of hepatocellular carcinoma when combined with α-fetoprotein in patients with cirrhosis undergoing surveillance.

07/23/2026

🚀 Another milestone for New Day Diagnostics.

We're pleased to share that a collaborative research study involving New Day Diagnostics has been published in JAMA Oncology.

This investigator-initiated study, led by the University Hospital of Nancy and an outstanding international team of clinical and scientific collaborators, explores circulating biomarkers for the early detection and management of liver cancer. New Day Diagnostics contributed reagents and technical support to the research.

We congratulate Abderrahim OUSSALAH, MD, PhD and all the investigators on this important scientific contribution and are grateful to have supported this collaborative effort. Advancing cancer diagnostics depends on strong partnerships among academic institutions, clinicians, and industry, and we remain committed to supporting high-quality research that has the potential to improve early cancer detection and patient outcomes.

Congratulations to all of the authors and collaborators on this publication.
hashtag hashtag hashtag hashtag hashtag hashtag hashtag hashtag

https://zurl.co/016TY

This diagnostic study evaluates whether methylated SEPT9 improves detection of hepatocellular carcinoma when combined with α-fetoprotein in patients with cirrhosis undergoing surveillance.

07/22/2026

The New Day Bioresearch Team will be at ADLM July 27-28th! Please come meet with us at the Luminex Booth #1701 or contact us to schedule a meeting!